Sesen Bio (SESN) Tops Q1 EPS by 1c

Sesen Bio (NASDAQ: SESN) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).

“We are very encouraged by the most recent analysis of our 12-month Phase 3 VISTA trial data, which will be the basis for our meetings with the FDA in May and June,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “We believe these preliminary data, along with a closely matched Phase 2 data set, support a compelling benefit-risk profile, and give us confidence in the regulatory approvability and strong commercial viability of Vicinium. The huge unmet need for patients with NMIBC is widely acknowledged and has been exacerbated by the recurring global shortage of BCG. We will continue to work closely with the FDA in our effort to expeditiously bring a product to market that has the potential to save and improve the lives of patients with NMIBC.”

For earnings history and earnings-related data on Sesen Bio (SESN) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Evogene chairman to address dissident shareholders on results call